CDKN2A and penile carcinoma: For example, the UpToDate authors Djajadiningrat et al. evaluated 212 patients with penile carcinoma and found that survival at 5 years was significantly higher in patients with elevated p16 than in those without p16 elevation (5-year overall survival of 96% versus 82%) [8].